Concepedia

Phi Tran

PT

Statistics

Publications

8

Citations

331

H-Index

8

Active since

2005

Affiliations

Novartis (Switzerland)(Current)

Novartis (United States)

Phi Tran is an author at Novartis (Switzerland) specializing in pharmacology, drug disposition, and pharmacokinetics.

Publications per year

2005–2019

8

Publications

8

Absorption, Metabolism, and Excretion of [14C]Vildagliptin, a Novel Dipeptidyl Peptidase 4 Inhibitor, in Humans

Handan He, Phi Tran, Hequn Yin et al. · Drug Metabolism and Disposition · 2008 · 139 citations

, , +8

Midostaurin, a Novel Protein Kinase Inhibitor for the Treatment of Acute Myelogenous Leukemia: Insights from Human Absorption, Metabolism, and Excretion Studies of a BDDCS II Drug

Handan He, Phi Tran, Helen Gu et al. · Drug Metabolism and Disposition · 2017 · 44 citations

, , +13

Transport properties of valsartan, sacubitril and its active metabolite (LBQ657) as determinants of disposition

Imad Hanna, Natalya Alexander, Matthew H. Crouthamel et al. · Xenobiotica · 2017 · 30 citations · Full text

, , +17

Disposition of Vildagliptin, a Novel Dipeptidyl Peptidase 4 Inhibitor, in Rats and Dogs

Handan He, Phi Tran, Hequn Yin et al. · Drug Metabolism and Disposition · 2008 · 29 citations

, , +12

Disposition of asciminib, a potent BCR-ABL1 tyrosine kinase inhibitor, in healthy male subjects

Phi Tran, Imad Hanna, Fabian Eggimann et al. · Xenobiotica · 2019 · 28 citations · Full text

, , +17

1–5 of 8